Phase 2Active, not recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia (ASCEND-QW)
A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia
- Sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 438 enrolled
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab
- Ages
- adults, older adults
- Registry
- NCT07477704
Full record on ClinicalTrials.gov
From the registry
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times
Primary outcomes
- Percent change in LDL-C
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered